Shares of Avidity Biosciences RNA have soared 36% in the past month, all thanks to a report issued by the Financial Times (FT ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

Scientists have decoded a century-old killer hiding in a preserved lung. New genetic evidence from 1918 reveals the virus was ...

Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration ...

From Johns Hopkins University School of Medicine, Charlotte J. Sumner, M.D., presents an editorial on a study by Richard S.

The global Live Cell RNA Detection Market is set for robust expansion, with valuation projected to rise from USD 3.4 billion ...

A new study suggests an enzyme unique to Homo sapiens may have made us more competitive water seekers than our closest ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...